These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23334813)

  • 1. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
    Dudley MN; Ambrose PG; Bhavnani SM; Craig WA; Ferraro MJ; Jones RN;
    Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan.
    Hsueh PR; Ko WC; Wu JJ; Lu JJ; Wang FD; Wu HY; Wu TL; Teng LJ
    J Microbiol Immunol Infect; 2010 Oct; 43(5):452-5. PubMed ID: 21075714
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD;
    Clin Infect Dis; 2011 Apr; 52(7):917-24. PubMed ID: 21427400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?
    Tamma PD; Powers JH
    Clin Infect Dis; 2013 Aug; 57(4):624-5. PubMed ID: 23658433
    [No Abstract]   [Full Text] [Related]  

  • 6. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by Pseudomonas aeruginosa isolates.
    Lin SP; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2012 Jun; 45(3):200-7. PubMed ID: 22209695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
    Van TT; Minejima E; Chiu CA; Butler-Wu SM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro activity of the newer beta-lactam antibiotics against 124 strains of gram-negative bacilli.
    Dixson S; Andrew JH
    Pathology; 1985 Oct; 17(4):636-9. PubMed ID: 3938006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
    Pottumarthy S; Deshpande LM; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
    Honderlick P; Gravisse J; Dardelle D; Cahen P
    Pathol Biol (Paris); 2007 Dec; 55(10):475-7. PubMed ID: 17904768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of Ro 17-2301, a new monobactam antibiotic].
    Roy C; Foz A; Segura C; Tirado M; Teixell M
    Med Clin (Barc); 1985 Jun; 85(5):183-6. PubMed ID: 3927089
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.
    Potz NA; Hope R; Warner M; Johnson AP; Livermore DM;
    J Antimicrob Chemother; 2006 Aug; 58(2):320-6. PubMed ID: 16735428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibility of Pseudomonas aeruginosa to aztreonam in comparison to other pseudomonas-active beta-lactam antibiotics and gentamicin].
    Wundt W; Lange KP; Baumgärtner M
    Arzneimittelforschung; 1985; 35(8):1322-5. PubMed ID: 3935123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of the monobactam Ro 17-2301 against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bremner DA
    J Antimicrob Chemother; 1985 Oct; 16(4):457-61. PubMed ID: 3934129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activities of three new antibacterial agents with aztreonam against gram-negative bacilli.
    Kafetzis DA; Legakis NJ
    Chemioterapia; 1987 Jun; 6(2 Suppl):110-2. PubMed ID: 3151330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.